Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 47Leukemia 14Myelodysplastic Syndromes 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Biphenotypic, Acute 9Recurrence 8Leukemia, Lymphocytic, Chronic, B-Cell 8Blast Crisis 7Lymphoma, Mantle-Cell 6Leukemia, Hairy Cell 6Leukemia, Monocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm, Residual 3Myeloproliferative Disorders 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3Burkitt Lymphoma 3Sarcoma, Myeloid 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Erythroblastic, Acute 2Graft vs Host Disease 2Thrombocythemia, Essential 1Targeted Therapy 1

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × Cladribine × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡